James Ferrara, MD, DSc, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, introduces the MAGIC model, which considers clinical features and biomarkers to predict outcomes of treatment for acute graft-versus-host disease (GvHD). This model can predict outcomes at day 14 of treatment more accurately than previous models which only consider clinical features. Dr Ferrara suggests day 14 should be a new endpoint in GvHD clinical trials. This interview took place at the 50th Annual Meeting of the EBMT in Glasgow, Scotland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
